SST中间神经元功能降低对抑郁症的影响
Effect of Somatostatin-Expressing Interneuron Deficits in Depression
摘要: 抑郁症(major depressive disorder)是一种常见的精神疾病，但其病理机制尚不清楚。近年来，研究发现神经网络的兴奋与抑制平衡失调可能是导致抑郁症的重要因素之一，该平衡主要由兴奋性谷氨酸能锥体神经元(pyramidal neuron)和抑制性γ-氨基丁酸(GABA)神经元协调完成。SST中间神经元是主要的抑制神经元，调节锥体神经元活动，参与应激反应，对应激有较高的易感性，在抑郁症患者背腹侧前额叶(dlPFC)、扣带回(ACC)、海马等脑区皆发现了SST mRNA或蛋白水平降低。本文将综述SST中间神经元功能及其功能降低对抑郁症影响的研究结果，包括在不同脑区(如前额叶、海马等)的表现、起因、相关的抑郁症药物研发。
Abstract: Major depressive disorder is a common mental illness, but its pathological mechanism is still unclear. In recent years, studies have found that imbalance of neural network excitability and inhibition may be one of the important factors leading to depression, which is mainly caused by the incoordination between excitatory glutamatergic pyramidal neurons and inhibitory gamma-aminobutyric acid neurons. Somatostatin-expressing interneurons, the main inhibitory neurons, regulate pyramidal neuronal activity, participate in stress response, and have a high susceptibility to stress. In the dorsal ventral frontal lobes (dlPFC), cingulate gyrus (ACC), hippocampus and other brain regions in patients with depression, researchers have found a decrease in SST mRNA and protein levels. This article will review the function of somatostatin-expressing interneuron and how its functional reduction impacts depression, including causes and performance.
文章引用：郭沉 (2019). SST中间神经元功能降低对抑郁症的影响. 心理学进展, 9(10), 1767-1777. https://doi.org/10.12677/AP.2019.910214

参考文献

[1] Ago, Y., Arikawa, S., Yata, M., Yano, K., Abe, M., Takuma, K., & Matsuda, T. (2008). Antidepressant-Like Effects of the Glucocorticoid Receptor Antagonist RU-43044 Are Associated with Changes in Prefrontal Dopamine in Mouse Models of Depression. Neuropharmacology, 55, 1355-1363.
[CrossRef] [PubMed]
[2] Atagun, M. I., Sikoglu, E. M., Soykan, C., Serdar Suleyman, C., Ulusoy-Kaymak, S., Caykoylu, A., Moore, C. M. et al. (2017). Perisylvian GABA Levels in Schizophrenia and Bipolar Disorder. Neuroscience Letters, 637, 70-74.
[CrossRef] [PubMed]
[3] Banasr, M., Lepack, A., Fee, C., Duric, V., Maldonado-Aviles, J., DiLeone, R., Sanacora, G. et al. (2017). Characterization of GABAergic Marker Expression in the Chronic Unpredictable Stress Model of Depression. Chronic Stress (Thousand Oaks), 1.
[CrossRef] [PubMed]
[4] Barja, G. (2002). Endogenous Oxidative Stress: Relationship to Aging, Longevity and Caloric Restriction. Ageing Research Reviews, 1, 397-411.
[CrossRef] 
[5] Bowley, M. P., Drevets, W. C., Ongur, D., & Price, J. L. (2002). Low Glial Numbers in the Amygdala in Major Depressive Disorder. Biological Psychiatry, 52, 404-412.
[CrossRef] 
[6] Brown, M. R., Rivier, C., & Vale, W. (1984). Central Nervous System Regulation of Adrenocorticotropin Secretion: Role of Somatostatins. Endocrinology, 114, 1546-1549.
[CrossRef] [PubMed]
[7] Bruunsgaard, H., & Pedersen, B. K. (2003). Age-Related Inflammatory Cytokines and Disease. Immunology and Allergy Clinics of North America, 23, 15-39.
[CrossRef] 
[8] Campbell, S., Marriott, M., Nahmias, C., & MacQueen, G. M. (2004). Lower Hippocampal Volume in Patients Suffering from Depression: A Meta-Analysis. American Journal of Psychiatry, 161, 598-607.
[CrossRef] [PubMed]
[9] Czeh, B., Varga, Z. K., Henningsen, K., Kovacs, G. L., Miseta, A., & Wiborg, O. (2015). Chronic Stress Reduces the Number of GABAergic Interneurons in the Adult Rat Hippocampus, Dorsal-Ventral and Region-Specific Differences. Hippocampus, 25, 393-405.
[CrossRef] [PubMed]
[10] Douillard-Guilloux, G., Guilloux, J. P., Lewis, D. A., & Sibille, E. (2013). Anticipated Brain Molecular Aging in Major Depression. The American Journal of Geriatric Psychiatry, 21, 450-460.
[CrossRef] [PubMed]
[11] Douillard-Guilloux, G., Lewis, D., Seney, M. L., & Sibille, E. (2017). Decrease in Somatostatin-Positive Cell Density in the Amygdala of Females with Major Depression. Depress Anxiety, 34, 68-78.
[CrossRef] [PubMed]
[12] Du, X., Serena, K., Hwang, W., Grech, A. M., Wu, Y. W. C., Schroeder, A., & Hill, R. A. (2018). Prefrontal Cortical Parvalbumin and Somatostatin Expression and Cell Density Increase during Adolescence and Are Modified by BDNF and Sex. Molecular and Cellular Neuroscience, 88, 177-188.
[CrossRef] [PubMed]
[13] Dubin, M. J., Mao, X., Banerjee, S., Goodman, Z., Lapidus, K. A., Kang, G., Shungu, D. C. et al. (2016). Elevated Prefrontal Cortex GABA in Patients with Major Depressive Disorder after TMS Treatment Measured with Proton Magnetic Resonance Spectroscopy. Journal of Psychiatry & Neuroscience, 41, E37-E45.
[CrossRef] [PubMed]
[14] Ebmeier, K. P., Donaghey, C., & Steele, J. D. (2006). Recent Developments and Current Controversies in Depression. The Lancet, 367, 153-167.
[CrossRef] 
[15] Engin, E., & Treit, D. (2009). Anxiolytic and Antidepressant Actions of Somatostatin: The Role of sst2 and sst3 Receptors. Psychopharmacology (Berl), 206, 281-289.
[CrossRef] [PubMed]
[16] Engin, E., Stellbrink, J., Treit, D., & Dickson, C. T. (2008). Anxiolytic and Antidepressant Effects of Intracerebroventricularly Administered Somatostatin: Behavioral and Neurophysiological Evidence. Neuroscience, 157, 666-676.
[CrossRef] [PubMed]
[17] Erickson, K. I., Prakash, R. S., Voss, M. W., Chaddock, L., Heo, S., McLaren, M., Kramer, A. F. et al. (2010). Brain-Derived Neurotrophic Factor Is Associated with Age-Related Decline in Hippocampal Volume. Journal of Neuroscience, 30, 5368-5375.
[CrossRef] 
[18] Erraji-Benchekroun, L., Underwood, M. D., Arango, V., Galfalvy, H., Pavlidis, P., Smyrniotopoulos, P., Sibille, E. et al. (2005). Molecular Aging in Human Prefrontal Cortex Is Selective and Continuous throughout Adult Life. Biological Psychiatry, 57, 549-558.
[CrossRef] [PubMed]
[19] Faron-Gorecka, A., Kusmider, M., Kolasa, M., Zurawek, D., Szafran-Pilch, K., Gruca, P., Dziedzicka-Wasylewska, M. et al. (2016). Chronic Mild Stress Alters the Somatostatin Receptors in the Rat Brain. Psychopharmacology (Berl), 233, 255-266.
[CrossRef] [PubMed]
[20] Faron-Gorecka, A., Kusmider, M., Solich, J., Kolasa, M., Pabian, P., Gruca, P., Dziedzicka-Wasylewska, M. et al. (2018). Regulation of Somatostatin Receptor 2 in the Context of Antidepressant Treatment Response in Chronic Mild Stress in Rat. Psychopharmacology (Berl), 235, 2137-2149.
[CrossRef] [PubMed]
[21] Fino, E., Packer, A. M., & Yuste, R. (2013). The Logic of Inhibitory Connectivity in the Neocortex. Neuroscientist, 19, 228-237.
[CrossRef] [PubMed]
[22] Fisher, D. A., & Brown, M. R. (1980). Somatostatin Analog: Plasma Catecholamine Suppression Mediated by the Central Nervous System. Endocrinology, 107, 714-718.
[CrossRef] [PubMed]
[23] French, L., Ma, T., Oh, H., Tseng, G. C., & Sibille, E. (2017). Age-Related Gene Expression in the Frontal Cortex Suggests Synaptic Function Changes in Specific Inhibitory Neuron Subtypes. Frontiers in Aging Neuroscience, 9, 162.
[CrossRef] [PubMed]
[24] Fuchs, T., Jefferson, S. J., Hooper, A., Yee, P. H., Maguire, J., & Luscher, B. (2017). Disinhibition of Somatostatin-Positive GABAergic Interneurons Results in an Anxiolytic and Antidepressant-Like Brain State. Molecular Psychiatry, 22, 920-930.
[CrossRef] [PubMed]
[25] Gabbay, V., Mao, X., Klein, R. G., Ely, B. A., Babb, J. S., Panzer, A. M., Shungu, D. C. et al. (2012). Anterior Cingulate Cortex Gamma-Aminobutyric Acid in Depressed Adolescents: Relationship to Anhedonia. Archives of General Psychiatry, 69, 139-149.
[CrossRef] [PubMed]
[26] Gentet, L. J., Kremer, Y., Taniguchi, H., Huang, Z. J., Staiger, J. F., & Petersen, C. C. (2012). Unique Functional Properties of Somatostatin-Expressing GABAergic Neurons in Mouse Barrel Cortex. Nature Neuroscience, 15, 607-612.
[CrossRef] [PubMed]
[27] Glorioso, C., Oh, S., Douillard, G. G., & Sibille, E. (2011). Brain Molecular Aging, Promotion of Neurological Disease and Modulation by Sirtuin 5 Longevity Gene Polymorphism. Neurobiology of Disease, 41, 279-290.
[CrossRef] [PubMed]
[28] Glorioso, C., Sabatini, M., Unger, T., Hashimoto, T., Monteggia, L. M., Lewis, D. A., & Mirnics, K. (2006). Specificity and Timing of Neocortical Transcriptome Changes in Response to BDNF Gene Ablation during Embryogenesis or Adulthood. Molecular Psychiatry, 11, 633-648.
[CrossRef] [PubMed]
[29] Gonchar, Y., & Burkhalter, A. (1997). Three Distinct Families of GABAergic Neurons in Rat Visual Cortex. Cerebral Cortex, 7, 347-358.
[CrossRef] [PubMed]
[30] Goshen, I., Kreisel, T., Ben-Menachem-Zidon, O., Licht, T., Weidenfeld, J., Ben-Hur, T., & Yirmiya, R. (2008). Brain Interleukin-1 Mediates Chronic Stress-Induced Depression in Mice via Adrenocortical Activation and Hippocampal Neurogenesis Suppression. Molecular Psychiatry, 13, 717-728.
[CrossRef] [PubMed]
[31] Guilloux, J. P., Douillard-Guilloux, G., Kota, R., Wang, X., Gardier, A. M., Martinowich, K., Sibille, E. et al. (2012). Molecular Evidence for BDNF- and GABA-Related Dysfunctions in the Amygdala of Female Subjects with Major Depression. Molecular Psychiatry, 17, 1130-1142.
[CrossRef] [PubMed]
[32] Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018). Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry, 75, 336-346.
[CrossRef] [PubMed]
[33] Herman, J. P., Ostrander, M. M., Mueller, N. K., & Figueiredo, H. (2005). Limbic System Mechanisms of Stress Regulation: Hypothalamo-Pituitary-Adrenocortical Axis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 29, 1201-1213.
[CrossRef] [PubMed]
[34] Hirschfeld, R. M. (2000). History and Evolution of the Monoamine Hypothesis of Depression. The Journal of Clinical Psychiatry, 61, 4-6.
[35] Hu, W., Zhang, M., Czeh, B., Flugge, G., & Zhang, W. (2010). Stress Impairs GABAergic Network Function in the Hippocampus by Activating Nongenomic Glucocorticoid Receptors and Affecting the Integrity of the Parvalbumin-Expressing Neuronal Network. Neuropsychopharmacology, 35, 1693-1707.
[CrossRef] [PubMed]
[36] Jaglin, X. H., Hjerling-Leffler, J., Fishell, G., & Batista-Brito, R. (2012). The Origin of Neocortical Nitric Oxide Synthase-Expressing Inhibitory Neurons. Frontiers in Neural Circuits, 6, 44.
[CrossRef] [PubMed]
[37] Karolewicz, B., Maciag, D., O’Dwyer, G., Stockmeier, C. A., Feyissa, A. M., & Rajkowska, G. (2010). Reduced Level of Glutamic Acid Decarboxylase-67 kDa in the Prefrontal Cortex in Major Depression. International Journal of Neuropsychopharmacology, 13, 411-420.
[CrossRef] 
[38] Keller, J., Gomez, R., Williams, G., Lembke, A., Lazzeroni, L., Murphy, G. M., & Schatzberg, A. F. (2017). HPA Axis in Major Depression: Cortisol, Clinical Symptomatology and Genetic Variation Predict Cognition. Molecular Psychiatry, 22, 527-536.
[CrossRef] [PubMed]
[39] Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., National Comorbidity Survey, R. et al. (2003). The Epidemiology of Major Depressive Disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289, 3095-3105.
[CrossRef] [PubMed]
[40] Klumpers, U. M., Veltman, D. J., Drent, M. L., Boellaard, R., Comans, E. F., Meynen, G., Hoogendijk, W. J. et al. (2010). Reduced Parahippocampal and Lateral Temporal GABAA-[11C]flumazenil Binding in Major Depression: Preliminary Results. European Journal of Nuclear Medicine and Molecular Imaging, 37, 565-574.
[CrossRef] [PubMed]
[41] Lewis, D. A., & Sweet, R. A. (2009). Schizophrenia from a Neural Circuitry Perspective: Advancing toward Rational Pharmacological Therapies. The Journal of Clinical Investigation, 119, 706-716.
[CrossRef] 
[42] Li, W., Papilloud, A., Lozano-Montes, L., Zhao, N., Ye, X., Zhang, X., Rainer, G. et al. (2018). Stress Impacts the Regulation Neuropeptides in the Rat Hippocampus and Prefrontal Cortex. Proteomics, 18, e1700408.
[CrossRef] [PubMed]
[43] Lin, L. C., & Sibille, E. (2013). Reduced Brain Somatostatin in Mood Disorders: A Common Pathophysiological Substrate and Drug Target? Frontiers in Pharmacology, 4, 110.
[CrossRef] [PubMed]
[44] Lin, L. C., & Sibille, E. (2015). Somatostatin, Neuronal Vulnerability and Behavioral Emotionality. Molecular Psychiatry, 20, 377-387.
[CrossRef] [PubMed]
[45] Ma, Y., Hu, H., Berrebi, A. S., Mathers, P. H., & Agmon, A. (2006). Distinct Subtypes of Somatostatin-Containing Neocortical Interneurons Revealed in Transgenic Mice. Journal of Neuroscience, 26, 5069-5082.
[CrossRef] 
[46] Machado-Vieira, R., Salvadore, G., DiazGranados, N., & Zarate, C. A. (2009). Ketamine and the Next Generation of Antidepressants with a Rapid Onset of Action. Pharmacology & Therapeutics, 123, 143-150.
[CrossRef] [PubMed]
[47] Marathe, S. V., D’Almeida P, L., Virmani, G., Bathini, P., & Alberi, L. (2018). Effects of Monoamines and Antidepressants on Astrocyte Physiology: Implications for Monoamine Hypothesis of Depression. Journal of Experimental Neuroscience, 12, 1179069518789149.
[CrossRef] [PubMed]
[48] Martinowich, K., Schloesser, R. J., Jimenez, D. V., Weinberger, D. R., & Lu, B. (2011). Activity-Dependent Brain-Derived Neurotrophic Factor Expression Regulates Cortistatin-Interneurons and Sleep Behavior. Molecular Brain, 4, 11.
[CrossRef] [PubMed]
[49] Mayberg, H. S. (2002). Modulating Limbic-Cortical Circuits in Depression: Targets of Antidepressant Treatments. Seminars in Clinical Neuropsychiatry, 7, 255-268.
[CrossRef] [PubMed]
[50] McEwen, B. S., Nasca, C., & Gray, J. D. (2016). Stress Effects on Neuronal Structure: Hippocampus, Amygdala, and Prefrontal Cortex. Neuropsychopharmacology, 41, 3-23.
[CrossRef] [PubMed]
[51] Millan, M. J. (2006). Multi-Target Strategies for the Improved Treatment of Depressive States: Conceptual Foundations and Neuronal Substrates, Drug Discovery and Therapeutic Application. Pharmacology & Therapeutics, 110, 135-370.
[CrossRef] [PubMed]
[52] Molchan, S. E., Lawlor, B. A., Hill, J. L., Martinez, R. A., Davis, C. L., Mellow, A. M., Sunderland, T. et al. (1991). CSF Monoamine Metabolites and Somatostatin in Alzheimer’s Disease and Major Depression. Biological Psychiatry, 29, 1110-1118.
[CrossRef] 
[53] Murayama, M., Perez-Garci, E., Nevian, T., Bock, T., Senn, W., & Larkum, M. E. (2009). Dendritic Encoding of Sensory Stimuli Controlled by Deep Cortical Interneurons. Nature, 457, 1137-1141.
[CrossRef] [PubMed]
[54] Nilsson, A., Stroth, N., Zhang, X., Qi, H., Falth, M., Skold, K., Svenningsson, P. et al. (2012). Neuropeptidomics of Mouse Hypothalamus after Imipramine Treatment Reveal Somatostatin as a Potential Mediator of Antidepressant Effects. Neuropharmacology, 62, 347-357.
[CrossRef] [PubMed]
[55] Pallis, E., Vasilaki, A., Fehlmann, D., Kastellakis, A., Hoyer, D., Spyraki, C., & Thermos, K. (2009). Antidepressants Influence Somatostatin Levels and Receptor Pharmacology in Brain. Neuropsychopharmacology, 34, 952-963.
[CrossRef] [PubMed]
[56] Pariante, C. M., & Lightman, S. L. (2008). The HPA Axis in Major Depression: Classical Theories and New Developments. Trends in Neurosciences, 31, 464-468.
[CrossRef] [PubMed]
[57] Ponomarev, I., Rau, V., Eger, E. I., Harris, R. A., & Fanselow, M. S. (2010). Amygdala Transcriptome and Cellular Mechanisms Underlying Stress-Enhanced Fear Learning in a Rat Model of Posttraumatic Stress Disorder. Neuropsychopharmacology, 35, 1402-1411.
[CrossRef] [PubMed]
[58] Post, R. M., Rubinow, D. R., Kling, M. A., Berrettini, W., & Gold, P. W. (1988). Neuroactive Substances in Cerebrospinal Fluid. Normal and Pathological Regulatory Mechanisms. Annals of the New York Academy of Sciences, 531, 15-28.
[CrossRef] [PubMed]
[59] Prevot, T. D., Gastambide, F., Viollet, C., Henkous, N., Martel, G., Epelbaum, J., Guillou, J. L. et al. (2017). Roles of Hippocampal Somatostatin Receptor Subtypes in Stress Response and Emotionality. Neuropsychopharmacology, 42, 1647-1656.
[CrossRef] [PubMed]
[60] Prevot, T. D., Viollet, C., Epelbaum, J., Dominguez, G., Beracochea, D., & Guillou, J. L. (2018). sst2-Receptor Gene Deletion Exacerbates Chronic Stress-Induced Deficits: Consequences for Emotional and Cognitive Ageing. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 86, 390-400.
[CrossRef] [PubMed]
[61] Rajkowska, G., Halaris, A., & Selemon, L. D. (2001). Reductions in Neuronal and Glial Density Characterize the Dorsolateral Prefrontal Cortex in Bipolar Disorder. Biological Psychiatry, 49, 741-752.
[CrossRef] 
[62] Ren, Z., Pribiag, H., Jefferson, S. J., Shorey, M., Fuchs, T., Stellwagen, D., & Luscher, B. (2016). Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment. Biological Psychiatry, 80, 457-468.
[CrossRef] [PubMed]
[63] Rozycka, A., & Liguz-Lecznar, M. (2017). The Space Where Aging Acts: Focus on the GABAergic Synapse. Aging Cell, 16, 634-643.
[CrossRef] [PubMed]
[64] Rudy, B., Fishell, G., Lee, S., & Hjerling-Leffler, J. (2011). Three Groups of Interneurons Account for Nearly 100% of Neocortical GABAergic Neurons. Developmental Neurobiology, 71, 45-61.
[CrossRef] [PubMed]
[65] Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Fava, M. et al. (2006). Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. American Journal of Psychiatry, 163, 1905-1917.
[CrossRef] [PubMed]
[66] Sanacora, G., Fenton, L. R., Fasula, M. K., Rothman, D. L., Levin, Y., Krystal, J. H., & Mason, G. F. (2006). Cortical Gamma-Aminobutyric Acid Concentrations in Depressed Patients Receiving Cognitive Behavioral Therapy. Biological Psychiatry, 59, 284-286.
[CrossRef] [PubMed]
[67] Sanacora, G., Mason, G. F., Rothman, D. L., Hyder, F., Ciarcia, J. J., Ostroff, R. B., Krystal, J. H. et al. (2003). Increased Cortical GABA Concentrations in Depressed Patients Receiving ECT. American Journal of Psychiatry, 160, 577-579.
[CrossRef] [PubMed]
[68] Scheich, B., Cseko, K., Borbely, E., Abraham, I., Csernus, V., Gaszner, B., & Helyes, Z. (2017). Higher Susceptibility of Somatostatin 4 Receptor Gene-Deleted Mice to Chronic Stress-Induced Behavioral and Neuroendocrine Alterations. Neuroscience, 346, 320-336.
[CrossRef] [PubMed]
[69] Scheich, B., Gaszner, B., Kormos, V., Laszlo, K., Adori, C., Borbely, E., Helyes, Z. et al. (2016). Somatostatin Receptor Subtype 4 Activation Is Involved in Anxiety and Depression-Like Behavior in Mouse Models. Neuropharmacology, 101, 204-215.
[CrossRef] [PubMed]
[70] Seney, M. L., Chang, L. C., Oh, H., Wang, X., Tseng, G. C., Lewis, D. A., & Sibille, E. (2013). The Role of Genetic Sex in Affect Regulation and Expression of GABA-Related Genes across Species. Frontiers in Psychiatry, 4, 104.
[CrossRef] [PubMed]
[71] Seney, M. L., Tripp, A., McCune, S., Lewis, D. A., & Sibille, E. (2015). Laminar and Cellular Analyses of Reduced Somatostatin Gene Expression in the Subgenual Anterior Cingulate Cortex in Major Depression. Neurobiology of Disease, 73, 213-219.
[CrossRef] [PubMed]
[72] Sheline, Y. I. (1996). Hippocampal Atrophy in Major Depression: A Result of Depression-Induced Neurotoxicity? Molecular Psychiatry, 1, 298-299.
[73] Shen, Q., Lal, R., Luellen, B. A., Earnheart, J. C., Andrews, A. M., & Luscher, B. (2010). Gamma-Aminobutyric Acid-Type A Receptor Deficits Cause Hypothalamic-Pituitary-Adrenal Axis Hyperactivity and Antidepressant Drug Sensitivity Reminiscent of Melancholic Forms of Depression. Biological Psychiatry, 68, 512-520.
[CrossRef] [PubMed]
[74] Shirayama, Y., Chen, A. C., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002). Brain-Derived Neurotrophic Factor Produces Antidepressant Effects in Behavioral Models of Depression. Journal of Neuroscience, 22, 3251-3261.
[CrossRef] 
[75] Sibille, E., Morris, H. M., Kota, R. S., & Lewis, D. A. (2011). GABA-Related Transcripts in the Dorsolateral Prefrontal Cortex in Mood Disorders. International Journal of Neuropsychopharmacology, 14, 721-734.
[CrossRef] 
[76] Sibille, E., Wang, Y., Joeyen-Waldorf, J., Gaiteri, C., Surget, A., Oh, S., Lewis, D. A. et al. (2009). A Molecular Signature of Depression in the Amygdala. American Journal of Psychiatry, 166, 1011-1024.
[CrossRef] [PubMed]
[77] Song, C., & Wang, H. (2011). Cytokines Mediated Inflammation and Decreased Neurogenesis in Animal Models of Depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35, 760-768.
[CrossRef] [PubMed]
[78] Soumier, A., & Sibille, E. (2014). Opposing Effects of Acute versus Chronic Blockade of Frontal Cortex Somatostatin-Positive Inhibitory Neurons on Behavioral Emotionality in Mice. Neuropsychopharmacology, 39, 2252-2262.
[CrossRef] [PubMed]
[79] Szafran-Pilch, K., Faron-Gorecka, A., Kolasa, M., Zurawek, D., Szlachta, M., Solich, J., Dziedzicka-Wasylewska, M. et al. (2017). Antidepressants Promote Formation of Heterocomplexes of Dopamine D2 and Somatostatin Subtype 5 Receptors in the Mouse Striatum. Brain Research Bulletin, 135, 92-97.
[CrossRef] [PubMed]
[80] Thompson Ray, M., Weickert, C. S., Wyatt, E., & Webster, M. J. (2011). Decreased BDNF, trkB-TK+ and GAD67 mRNA Expression in the Hippocampus of Individuals with Schizophrenia and Mood Disorders. Journal of Psychiatry & Neuroscience, 36, 195-203.
[CrossRef] [PubMed]
[81] Thompson, S. M., Kallarackal, A. J., Kvarta, M. D., Van Dyke, A. M., LeGates, T. A., & Cai, X. (2015). An Excitatory Synapse Hypothesis of Depression. Trends in Neurosciences, 38, 279-294.
[CrossRef] [PubMed]
[82] Tripp, A., Kota, R. S., Lewis, D. A., & Sibille, E. (2011). Reduced Somatostatin in Subgenual Anterior Cingulate Cortex in Major Depression. Neurobiology of Disease, 42, 116-124.
[CrossRef] [PubMed]
[83] Tripp, A., Oh, H., Guilloux, J. P., Martinowich, K., Lewis, D. A., & Sibille, E. (2012). Brain-Derived Neurotrophic Factor Signaling and Subgenual Anterior Cingulate Cortex Dysfunction in Major Depressive Disorder. American Journal of Psychiatry, 169, 1194-1202.
[CrossRef] [PubMed]
[84] Valentine, G. W., & Sanacora, G. (2009). Targeting Glial Physiology and Glutamate Cycling in the Treatment of Depression. Biochemical Pharmacology, 78, 431-439.
[CrossRef] [PubMed]
[85] Vincent, M. Y., Hussain, R. J., Zampi, M. E., Sheeran, K., Solomon, M. B., Herman, J. P., Jacobson, L. et al. (2013). Sensitivity of Depression-Like Behavior to Glucocorticoids and Antidepressants Is Independent of Forebrain Glucocorticoid Receptors. Brain Research, 1525, 1-15.
[CrossRef] [PubMed]
[86] Viollet, C., Lepousez, G., Loudes, C., Videau, C., Simon, A., & Epelbaum, J. (2008). Somatostatinergic Systems in Brain: Networks and Functions. Molecular and Cellular Endocrinology, 286, 75-87.
[CrossRef] [PubMed]
[87] Viollet, C., Vaillend, C., Videau, C., Bluet-Pajot, M. T., Ungerer, A., L’Heritier, A., Epelbaum, J. et al. (2000). Involvement of sst2 Somatostatin Receptor in Locomotor, Exploratory Activity and Emotional Reactivity in Mice. European Journal of Neuroscience, 12, 3761-3770.
[CrossRef] [PubMed]
[88] Wang, J., Jing, L., Toledo-Salas, J. C., & Xu, L. (2015). Rapid-Onset Antidepressant Efficacy of Glutamatergic System Modulators: The Neural Plasticity Hypothesis of Depression. Neuroscience Bulletin, 31, 75-86.
[CrossRef] [PubMed]
[89] Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., & Bruns, C. (2003). Opportunities in Somatostatin Research: Biological, Chemical and Therapeutic Aspects. Nature Reviews Drug Discovery, 2, 999-1017.
[CrossRef] [PubMed]
[90] Wohleb, E. S., Wu, M., Gerhard, D. M., Taylor, S. R., Picciotto, M. R., Alreja, M., & Duman, R. S. (2016). GABA Interneurons Mediate the Rapid Antidepressant-Like Effects of Scopolamine. The Journal of Clinical Investigation, 126, 2482-2494.
[CrossRef] 
[91] Xu, H., Jeong, H. Y., Tremblay, R., & Rudy, B. (2013). Neocortical Somatostatin-Expressing GABAergic Interneurons Disinhibit the Thalamorecipient Layer 4. Neuron, 77, 155-167.
[CrossRef] [PubMed]
[92] Yeung, M., & Treit, D. (2012). The Anxiolytic Effects of Somatostatin Following Intra-Septal and Intra-Amygdalar Microinfusions Are Reversed by the Selective sst2 Antagonist PRL2903. Pharmacology Biochemistry and Behavior, 101, 88-92.
[CrossRef] [PubMed]
[93] Yeung, M., Engin, E., & Treit, D. (2011). Anxiolytic-Like Effects of Somatostatin Isoforms SST 14 and SST 28 in Two Animal Models (Rattus norvegicus) after Intra-Amygdalar and Intra-Septal Microinfusions. Psychopharmacology (Berl), 216, 557-567.
[CrossRef] [PubMed]
[94] Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Luckenbaugh, D. A. et al. (2012). Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial. Biological Psychiatry, 71, 939-946.
[CrossRef] [PubMed]